Conformationally stabilized cell adhesion peptides

Details Conformationally stabilized cell adhesion peptides Conformationally stabilized cell adhesion peptides

2006-04-18

2006-04-18

Tate, Christopher R. (Department: 1654)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

Tripeptides, e.g., tripeptide thyroliberin , etc.

C530S317000, C514S012200, C514S002600

Reexamination Certificate

active

07030213

ABSTRACT:
Novel synthetic Arg-Gly-Asp containing peptides which have high affinity and specificity for their receptors by virtue of restrictions on their stereochemical conformation. Such restrictions can be provided by cyclization, by inclusion into a constraining conformational structure such as a helix, by providing an additional chemical structure such as an amide or an enantiomer of a naturally occurring amino acid, or by other methods. In particular, there are provided cyclic peptides having increased affinity and selectivity for the certain receptors over that of linear, Arg-Gly-Asp-containing synthetic peptides.

REFERENCES:
patent: 4517666 (1985-05-01), Ando
patent: 4517686 (1985-05-01), Ruoslahti et al.
patent: 4547489 (1985-10-01), Goldstein
patent: 4578079 (1986-03-01), Ruoslahti et al.
patent: 4589881 (1986-05-01), Pierschbacher et al.
patent: 4605512 (1986-08-01), Schaller et al.
patent: 4614517 (1986-09-01), Ruoslahti et al.
patent: 4661111 (1987-04-01), Ruoslahti et al.
patent: 4683291 (1987-07-01), Zimmerman et al.
patent: 4789734 (1988-12-01), Pierschbacher
patent: 4792525 (1988-12-01), Ruoslahti et al.
patent: 4857508 (1989-08-01), Adams et al.
patent: 4879313 (1989-11-01), Tjoeng et al.
patent: 4929601 (1990-05-01), Brunetti et al.
patent: 4943562 (1990-07-01), Jolles et al.
patent: 5023233 (1991-06-01), Nutt et al.
patent: 5037808 (1991-08-01), Tjoeng
patent: 5041380 (1991-08-01), Ruoslahti et al.
patent: 5981468 (1999-11-01), Pierschbacher et al.
patent: 3841763 (1990-06-01), None
patent: 0 114 759 (1984-01-01), None
patent: 0 317 053 (1988-05-01), None
patent: 0 275 748 (1988-07-01), None
patent: 0 338 634 (1989-10-01), None
patent: 0 341 915 (1989-11-01), None
patent: 0 368 486 (1990-05-01), None
patent: 2 207 922 (1989-02-01), None
patent: WO 89/00200 (1989-01-01), None
patent: WO 89/04837 (1989-06-01), None
patent: WO 89/05150 (1989-07-01), None
patent: WO 89/07609 (1989-08-01), None
patent: WO 90/00178 (1990-01-01), None
patent: WO 90/02751 (1990-03-01), None
patent: WO 90/06943 (1990-06-01), None
patent: WO 90/15620 (1990-12-01), None
patent: WO 91/01331 (1991-02-01), None
patent: WO 91/15515 (1991-10-01), None
patent: WO 91/15516 (1991-10-01), None
Hayman et al. 1985 (J. Cell Bio. 100: 1948) (p. 1951, second column, first paragraph).
Pytela et al., “Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp-specific adhesion receptors,”Science231:1559-1562 (1985).
Ratner et al., “Complete nucleotide sequence of the AIDS virus, HTLV-III,”Nature313:277-284 (1985).
Rauvala et al., “The adhesive and neurite-promoting molecule p30: analysis of the amino-terminal sequence and production of antipeptide antibodies that detect p30 at the surface of neuroblastoma cells and of brain neurons,”J. Cell. Biol. 107:2293-2305 (1988).
Recny et al., “Characterization of the α-peptide released upon protease activation of pyruvate oxidase,”J. Biol. Chem. 260:14287-14291 (1985).
Ruggeri et al., “Inhibition of platelet function with synthetic peptides designed to be high-affinity antagonists of fibrinogen binding to platelets,”Proc. Natl. Acad. Sci. USA83:5708-5712 (1986).
Ruoslahti and Pierschbacher, “Arg-Gly-Asp: a versatile cell recognition signal,”Cell44:517-513 (1986).
Ruoslahti and Pierschbacher, “Arg-Gly-Asp: a cellular recognition system for positional signal,”Falk. Symposium43:239-244 (1987).
Ruoslahti, “Integrins,”J. Clin. Invest.87:1-5 (1991).
Sakakibara et al., “Synthesis of (Pro-Hyp-Gly)nof defined molecular weights evidence for stabilization of collagen triple helix by hydroxypyroline,”BBA303:198-202 (1973).
Shebuski et al., “Characterization and Platelet inhibitory activity of bitistatin, a potent Arginine-Glycine-Asparatic acid-containing peptide from the venom of viperBitis arietans,” J. Biol. Chem. 264:21550-21556 (1989).
Ali et al., “Potent fibrinogen receptor antagonists bearing conformational constraints,”Peptides Proc. 11th Amer. Peptide Symposium, La Jolla, CA, Marshall & Rivier, eds. (Jul. 9-14, 1989).
Barker, “Synthesis of cylic hexapeptides containing the Arg-Gly-Asp-Val sequence as potential inhibitors of fibonectin mediated cell adhesion,”Protein Society 2nd Symposium(1987).
Bodanszky,Principles of Peptide SynthesisSpringer-Verlag pp. 217-222 (1984).
Bond and Strydom, “Amino acid sequence of bovine angiogenin,”Biochemistry28:6110-6113 (1989).
Chao et al., “Agkistrodon piscivorus piscivirusplatelet aggregation inhibitor: a potent inhibitor of a platelet activation,”Proc. Natl. Acad. Sci. USA86:8050-8054 (1989).
Cheresh, “Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins,”Chem. Abstractvol. 104, abstract No. 183980c (1986).
D'Souza et al., “Chemical cross-linking of Arginyl-Glycly-Aspartic acid peptides to an adhesion receptor on platelets,”J. Biol. Chem. 263:3943-3951 (1988).
Davies et al., “Synthetic peptide mimics of the active domain of fibronectin,”Biochem. Soc. Trans. 18:11326-11328 (1990).
Dayhoff et al., “A model of evolutionary change in proteins,”Atlas of Protein Sequences and Structure5:89-99 (1972).
Dennis et al., “Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors,”Proc. Natl. Acad. Sci. USA87:2471-2475 (1989).
Drickamer et al., “Mannose-binding proteins isolated from rat liver contain carbohydrate-recognition domains linked to collagenous tails,”J. Biol. Chem. 261:6878-6887 (1986).
Dufton and Hider, “Conformational properties of the neurotoxins and cytotoxins isolated from elapid snake venoms,”CRC Crit. Rev. Biochem. 14:113-171 (1983).
Edwards and Spatola, “In vitro activity profiles of cyclic and linear enkephalin pseudopeptide analogs,”Biochem. Biophys. Res. Commun. 136(2):730-736 (1986).
Gan et al., “A potent platelet aggregation inhibitor from the venom of the viper,echis carinatus,” J. Biol. Chem. 263 (36):19827-19832 (1988).
Gardner and Hynes, “Interaction of fibronectin with its receptor on platelets,”Cell42:439-448 (1985).
Gero and Spatola, “Synthesis and Biological Activity of a cyclic pseudohexapeptide analog of somatostatin,”Biochem. Biophys. Res. Commun. 120 (3):840-845 (1984).
Garsky et al., “Chemical synthesis of echistatin, a potent inhibitor of platelet aggregation fromEchis carinatus: synthesis and biological activity of selected analogs,”Proc. Natl. Acad. Sci. USA86:4022-4026 (1989).
Gartner and Bennett, “The tetrapeptide analogue of the cell attachement site if fibronectin inhibits platelet aggregation and fibronogen binding to activate platelets,”J. Biol. Chem. 260:11891-11894 (1985).
Gehlsen et al., “Inhibition of in vitro tumor cell invasion by Arg-Gly-Asp-containing synthetic peptides,”J. of Cell Biology106:925-930 (1988).
Ginsberg et al., “Inhibition of fibronectin binding to platelets by proteolytic fragments and synthetic peptides which support fibroblast adhesion,”J. Biol. Chem. 260:3931-3936 (1985).
Harvey et al., “Toxins from mamba venoms that facilitate neuromuscular transmission”J. Taxicol.—Toxin Reviews3:91-137 (1984).
Haskel and Abendschein, “Deaggregation of human platelets in vitro by an RGD analog antagonist of platelet glycoprotein IIb/IIIa receptors,”Thromb. Res. 56:687-695 (1988).
Haverstick et al., “Inhibitions of platelet adhesion to fibronectin, fibrinogen and von Willebrand factor substrates by a synthetic tetrapeptide derived from the cell-binding domain of fibronectin, ”Blood66:946-952 (1985).
Hruby, “Conformational restrictions of biologically active peptides via amino acid side chain groups,”Life Science, 31(3):189-199 (1982).
Huang et al., “

Affiliated with

Also associated with

Rating

Conformationally stabilized cell adhesion peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Conformationally stabilized cell adhesion peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conformationally stabilized cell adhesion peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3555090